We spoke with the National Institute for Health Research’s (NIHR) senior business development manager, Anjna Rising, to learn how the NIHR is approaching innovative clinical trials and fosterin
With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest
